Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

2002 • 6,428 citations

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

2004 • 5,895 citations

Repeated observation of breast tumor subtypes in independent gene expression data sets

2003 • 5,356 citations

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

2005 • 5,199 citations

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

2005 • 4,901 citations

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

2007 • 4,498 citations

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

2006 • 4,319 citations

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

2006 • 3,623 citations

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

2005 • 2,658 citations

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

2005 • 2,221 citations

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

2007 • 1,991 citations

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

2007 • 1,788 citations

Concordance among Gene-Expression–Based Predictors for Breast Cancer

2006 • 1,336 citations

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

2005 • 1,225 citations

The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells

2007 • 985 citations

The Decrease in Breast-Cancer Incidence in 2003 in the United States

2007 • 980 citations

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

2005 • 956 citations

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

2007 • 889 citations

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

2008 • 806 citations

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

2007 • 605 citations

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

2009 • 572 citations

Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status

2007 • 443 citations

Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831

2002 • 401 citations

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

2000 • 328 citations

Minimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast Carcinoma

2003 • 269 citations

2–46 Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

2006 • 259 citations

1–1 Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

2007 • 192 citations

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer

2006 • 128 citations

Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays

2006 • 110 citations

Quality Assurance in Immunohistochemistry

2002 • 104 citations

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years??? Adjuvant Treatment for Breast Cancer

2005 • 75 citations

Minimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast Carcinoma

2003 • 56 citations

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

2005 • 43 citations

Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors

2008 • 27 citations

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome

2006 • 24 citations

The Decrease in Breast-Cancer Incidence in 2003 in the United States

2008 • 16 citations